Proposed US rules may restrict international biotech partnerships with China
Draft regulations from the U.S. Treasury Department could significantly limit American companies’ collaborations with Chinese entities in biotechnology. The proposed COINS rules aim to safeguard national security by restricting financial ties, potentially disrupting ongoing research and development partnerships across borders. Experts warn this could slow innovation and global progress in life sciences.
The U.S. Treasury Department has released draft regulations under the COINS (China Overseas Investment and National Security) framework that could restrict American biotechnology firms from partnering with Chinese entities. These proposed rules aim to protect national security by limiting financial ties in sensitive sectors, particularly in life sciences research and development. While specific details such as implementation timelines or exact thresholds for restrictions are not included in the summary, the focus on biotech signals a growing concern over intellectual property risks and potential dual-use technologies. The draft applies broadly to collaborations involving funding, joint ventures, or shared data, which may affect ongoing projects across multiple U.S.-China research initiatives.
This move follows increasing scrutiny of China’s role in global scientific innovation, especially after prior actions by the U.S. government to restrict technology transfers and tighten export controls on advanced biotech tools. The Treasury Department’s initiative builds on earlier efforts by agencies like the Department of Commerce and the Committee on Foreign Investment in the United States (CFIUS), which have already reviewed or blocked certain cross-border deals. The push reflects a broader strategic shift toward decoupling critical technology sectors from China, driven by national security concerns rather than purely economic factors.
The primary actors are U.S. biotech companies
The proposed COINS rules could disrupt international scientific collaboration, particularly in biotechnology, where cross-border research has historically accelerated innovation. U.S. academic institutions and private firms may face increased compliance burdens, potentially deterring partnerships that once drove breakthroughs in medicine and public health. This shift may also affect global supply chains for biopharmaceuticals and diagnostics, especially if China responds with reciprocal restrictions. The long-term impact on medical progress—such as vaccine development or treatments for chronic diseases—could be significant, particularly in regions reliant on shared research data. A comparable precedent is the 2018 U.S. ban on Huawei-related technology transfers, which reshaped global tech supply chains and prompted retaliatory measures. While not identical, that case illustrates how national security concerns can rapidly alter international cooperation in high-tech fields. The current